Patents Assigned to Memorial Sloan-Kettering Cancer Center
  • TRANSGENIC T CELL AND CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND RELATED METHODS
    Publication number: 20220411753
    Abstract: The invention provides a T cell wherein one or more therapeutic transgenes is integrated at a within the genome of the cell such that expression of the transgene is under control of an endogenous promoter of the T cell. The invention additional provides methods of making and using such cells to treat a subject with T cell therapy. The invention also provides a T cell wherein a recombinant nucleic acid sequence encoding a chimeric antigen receptor (CAR) is integrated at a first site within the genome of the cell such that the CAR is expressed by the cell at the surface of the cell, and wherein integration of the nucleic acid encoding the CAR at the first site reduces or prevents expression of a functional T cell receptor (TCR) complex at the surface of the cell. The invention additional provides methods of making and using such cells to treat a subject with CAR therapy.
    Type: Application
    Filed: May 25, 2022
    Publication date: December 29, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Michel W. J. Sadelain, Justin Gabriel Andre Francois Eyquem, Jorge Mansilla-Soto
  • Systems and methods for multiple instance learning for classification and localization in biomedical imaging
    Patent number: 11538155
    Abstract: The present disclosure is directed to systems and methods for classifying biomedical images. A feature classifier may generate a plurality of tiles from a biomedical image. Each tile may correspond to a portion of the biomedical image. The feature classifier may select a subset of tiles from the plurality of tiles by applying an inference model. The subset of tiles may have highest scores. Each score may indicate a likelihood that the corresponding tile includes a feature indicative of the presence of the condition. The feature classifier may determine a classification result for the biomedical image by applying an aggregation model. The classification result may indicate whether the biomedical includes the presence or lack of the condition.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: December 27, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Thomas Fuchs, Gabriele Campanella
  • COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
    Publication number: 20220401475
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward tumor and pathogen antigens. It relates to immunoresponsive cells comprising two or more chimeric antigen receptors (CARs), wherein the CARs comprise different intracellular signaling domains, in particular, the intracellular signaling domains of the CARs comprise different co-stimulatory molecules.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 22, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Mohamad Hamieh, Judith Feucht
  • Anti-CD33 antibody agents
    Patent number: 11529371
    Abstract: Provided are anti-CD33 antibody agents, including anti-CD33 antibody agents in an IgG-scFv format. Various methods and reagents related thereto are also provided, including for example for the detection, prevention, and/or therapeutical treatment of CD33-related diseases, in particular, leukemias such as AML.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: December 20, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Sayed Shahabuddin Hoseini, Nai-Kong V. Cheung
  • Catheter control mechanism with magnetic resonance imaging-compatible torque
    Patent number: 11523873
    Abstract: Exemplary embodiments of the present disclosure can include for example, an apparatus, which can include a manipulating arrangement configured to cause a medical device to move, where a portion of the manipulating arrangement can be partly composed of a non-magnetic material, and a computer arrangement in a communication with the manipulating arrangement, and configured to remotely operate the manipulating arrangement. The computer arrangement can include a computer. The communication can be a wired or wireless communication. The medical device can include (i) a catheter, (ii) an endoscope, or (iii) a needle. The manipulating arrangement can include a catheter as the medical device that can be attached to a manipulator.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: December 13, 2022
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Kamran Nazim, Maribel Vazquez, Joanne Lee, Estefany Condo, Luis Cardoso, Stephen Solomon, Govindarajan Srimathveeravalli
  • Methods and compositions for treating cancer using peptide nucleic acid-based agents
    Patent number: 11518996
    Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 6, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jeffrey H. Rothman, Gary K. Schwartz
  • WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME
    Publication number: 20220380423
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 1, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David SCHEINBERG, Javier Pinilla-Ibarz, Rena May
  • LANTIBIOTICS, LANTIBIOTIC-PRODUCING BACTERIA, COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
    Publication number: 20220370547
    Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.
    Type: Application
    Filed: December 28, 2021
    Publication date: November 24, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero
  • T cell receptor-like antibodies specific for Foxp3-derived peptides
    Patent number: 11505599
    Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 22, 2022
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
  • CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
    Publication number: 20220363775
    Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MILLENNIUM PHARMACEUTICALS, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Sascha P. Haubner, Jorge Mansilla-Soto, Xingyue He, Gary Shapiro
  • Deep multi-magnification networks for multi-class image segmentation
    Patent number: 11501434
    Abstract: Described herein are Deep Multi-Magnification Networks (DMMNs). The multi-class tissue segmentation architecture processes a set of patches from multiple magnifications to make more accurate predictions. For the supervised training, partial annotations may be used to reduce the burden of annotators. The segmentation architecture with multi-encoder, multi-decoder, and multi-concatenation outperforms other segmentation architectures on breast datasets, and can be used to facilitate pathologists' assessments of breast cancer in margin specimens.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 15, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Thomas Fuchs, David Joon Ho
  • SMALL MOLECULE INHIBITORS OF Id PROTEINS
    Publication number: 20220356163
    Abstract: The present technology relates generally to compounds, compositions, and methods useful for treating, preventing, and/or ameliorating pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease in a subject.
    Type: Application
    Filed: September 30, 2020
    Publication date: November 10, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Robert BENEZRA, Ouathek OUERFELLI, Guangli YANG
  • ANTI-PARASITIC COMPOUNDS AND USES THEREOF
    Publication number: 20220340557
    Abstract: The present disclosure provides compounds of Formula (I?), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.
    Type: Application
    Filed: November 22, 2021
    Publication date: October 27, 2022
    Applicants: Memorial Sloan-Kettering Cancer Center, The Regents of the University of California, University of Central Florida Research Foundation, Inc., The Broad Institute, Inc.
    Inventors: Derek Shieh Tan, Corinne N. Foley, Gustavo Moura-Letts, James McKerrow, Sivaraman Dandapani, Rahul Edwankar, Alyssa Verano, Debopam Chakrabarti, Bracken Roberts
  • REPLICATION COMPETENT ATTENUATED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT THE EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY
    Publication number: 20220339221
    Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.
    Type: Application
    Filed: August 7, 2020
    Publication date: October 27, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang DENG, Stewart SHUMAN, Jedd WOLCHOK, Taha MERGHOUB, Weiyi WANG, Peihong DAI, Ning Yang
  • Methods of administering anti-OX40 antibodies
    Patent number: 11472883
    Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: October 18, 2022
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
  • Methods and compositions for reducing infection
    Patent number: 11471495
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 18, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • Innate metabolic imaging of cellular systems
    Patent number: 11464448
    Abstract: Described herein are systems and methods for image-based (e.g., MRI-based) spatial and temporal mapping of macrophages and other cell types, without the need for image contrast agents. These systems and methods are particularly useful for imaging macrophages because they naturally store metabolites, such as iron. Alternatively, the systems and methods described herein can be used where contrast agents are administered, rather than looking only at endogenous metabolite deposits.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 11, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Avigdor Leftin, Jason Koutcher
  • Treating metastatic cancer and model systems for metastatic disease
    Patent number: 11464874
    Abstract: The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 11, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Karuna Ganesh, Manuel Valiente, Joan Massague
  • ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF USE
    Publication number: 20220315660
    Abstract: The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
    Type: Application
    Filed: February 11, 2021
    Publication date: October 6, 2022
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Chen Liu
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20220313817
    Abstract: This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 6, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventor: David A. SCHEINBERG